AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26715196 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge multi-vitamin multi-mineral supplementation (including folate and iron)
Number of subjects: 3954
Study 26715196 — intervention group
Group type: COMPARATOR
Intervention: Routine care (folate and iron)
Number of subjects: 3954
Study 26715196 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge cotrimoxazole prophylaxis
Number of subjects: 3954
Study 26715196 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 3954
Study 24384959 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP‐TCA directed chemotherapy regimen (specific regimens include paclitaxel+carboplatin, paclitaxel+oxaliplatin, bleomycin+ifosfamide+cisplatin, bleomycin+vincristine+cisplatin, fluorouracil+cisplatin, gemcitabine+cisplatin)
Number of subjects: 72
Study 24384959 — intervention group
Group type: COMPARATOR
Intervention: Control group chemotherapy regimen confirmed by clinical experience
Number of subjects: 72
Study 20473991 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean plus fish oil emulsion (1.0 and 0.2 g per kg per day respectively)
Number of subjects: 206
Study 20473991 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil alone (1.2 g per kg bodyweight per day; control group)
Number of subjects: 206
Study 19052244 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening of quadriceps plus strengthening of hip abductor and lateral rotator muscles
Number of subjects: 14
Study 19052244 — intervention group
Group type: COMPARATOR
Intervention: Strengthening of quadriceps
Number of subjects: 14
Study 15843115 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored, multidimensional intervention (15 structured sessions of 90 minutes each)
Number of subjects: 943
Study 12610030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways To Change (PTC) plus free blood testing strips
Number of subjects: 1029
Study 12610030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways To Change (PTC)
Number of subjects: 1029
Study 12610030 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU) plus free blood testing strips
Number of subjects: 1029
Study 12610030 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 1029
Study 12610030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways To Change (PTC) for healthy eating
Number of subjects: 1029
Study 12610030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways To Change (PTC) for healthy eating with increased SMBG frequency
Number of subjects: 1029
Study 10485555 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV with fluid‐gas exchange and endolaser
Number of subjects: 283
Study 8984878 — intervention group
Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope in neutral position
Number of subjects: 177
Study 8984878 — intervention group
Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope in best position
Number of subjects: 177
Study 8984878 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 177
Study 8984878 — intervention group
Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope in patients where vocal cords could not be seen with Macintosh
Number of subjects: 177
Study 1817898 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine 3% with Felypressin
Number of subjects: 0
Study 1817898 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 4% with Epinephrine 1/200,000
Number of subjects: 0
Study 1817898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% with Epinephrine 1/100,000
Number of subjects: 0
Study 1817898 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 4% with Epinephrine 1/100,000
Number of subjects: 0
Study 7040158 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol and antacid
Number of subjects: 28
Study 7040158 — intervention group
Group type: COMPARATOR
Intervention: Placebo and antacid
Number of subjects: 28
Study 31263555 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth application (smartphone equipped)
Number of subjects: 520
Study 31263555 — intervention group
Group type: COMPARATOR
Intervention: Paper-based control
Number of subjects: 520
Study 28274246 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMCs stimulated for cytokine production after day 3
Number of subjects: 95
Study 28274246 — intervention group
Group type: COMPARATOR
Intervention: TNF‐α production less than 250 pg/ml after lipopolysaccharide stimulation on day 3
Number of subjects: 95
Study 28274246 — intervention group
Group type: COMPARATOR
Intervention: Cardiovascular failure on admission
Number of subjects: 95
Study 27208415 — intervention group
Group type: EXPERIMENTAL
Intervention: Trehalose (100 g/day)
Number of subjects: 32
Study 27208415 — intervention group
Group type: COMPARATOR
Intervention: Maltose (isocaloric control)
Number of subjects: 32
Study 24954518 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-lapse monitoring (Group A)
Number of subjects: 138
Study 24954518 — intervention group
Group type: COMPARATOR
Intervention: Conventional incubator (Group B)
Number of subjects: 138
Study 23032742 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with modified HLA class I tumor peptides (Melan‐A/MART‐1([27L]), gp100([210M]), NY‐ESO‐1([165V]), and Survivin([97M])) emulsified in Montanide ISA51, injected subcutaneously with cyclophosphamide (300 mg/m(2)) and low‐dose IL‐2 (3 × 10(6) IU).
Number of subjects: 43
Study 23032742 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group).
Number of subjects: 43
Study 23032742 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with modified HLA class I tumor peptides.
Number of subjects: 43
Study 19541691 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-gentamicin sponges applied between sternal halves in addition to routine intravenous antibiotics
Number of subjects: 1359
Study 19541691 — intervention group
Group type: COMPARATOR
Intervention: Control group (previous study with intravenous prophylaxis only)
Number of subjects: 1359
Study 17641452 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-curricular aerobic dynamic physical activity (swimming, water games, folk dance, soccer) for 35 weeks, 45 min of physical classes plus three 60 min sessions weekly
Number of subjects: 31
Study 17641452 — intervention group
Group type: COMPARATOR
Intervention: Control group (43 overweight or obese boys) with only two curricular physical education classes weekly
Number of subjects: 31
Study 17641452 — intervention group
Group type: COMPARATOR
Intervention: Control group (75 non-overweight and non-obese boys)
Number of subjects: 31
Study 17641452 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-curricular aerobic dynamic physical activity
Number of subjects: 31
Study 15365965 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intraperitoneal immunoglobulin (IgG) 2 mL (320 mg) with every exchange
Number of subjects: 24
Study 15365965 — intervention group
Group type: COMPARATOR
Intervention: Empiric antibiotic treatment (2-week IP ampicillin+sulbactam/netilmycin combination)
Number of subjects: 24
Study 12226037 — intervention group
Group type: EXPERIMENTAL
Intervention: Distractive auditory stimuli (DAS)
Number of subjects: 24
Study 12226037 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DAS)
Number of subjects: 24
Study 11231701 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 0.2 mg/d
Number of subjects: 151
Study 11231701 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 0.4 mg/d
Number of subjects: 151
Study 11231701 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 0.6 mg/d
Number of subjects: 151
Study 11231701 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 0.8 mg/d
Number of subjects: 151
Study 11231701 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 1.0 mg/d
Number of subjects: 151
Study 11231701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 9381718 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils in patients with internal endometriosis
Number of subjects: 16
Study 9381718 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy women)
Number of subjects: 16
Study 8349067 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg/d)
Number of subjects: 144
Study 8349067 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg/d)
Number of subjects: 144
Study 3768492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of trimazosin
Number of subjects: 6
Study 3768492 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of trimazosin
Number of subjects: 6
Study 3768492 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hydroxytrimazosin (metabolite)
Number of subjects: 6
Study 28988765 — intervention group
Group type: EXPERIMENTAL
Intervention: UroRCC multi-peptide vaccine
Number of subjects: 19
Study 28988765 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (metastasectomy only)
Number of subjects: 19
Study 30355323 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous adipose tissue injection
Number of subjects: 54
Study 30355323 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid injection
Number of subjects: 54
Study 27082493 — intervention group
Group type: EXPERIMENTAL
Intervention: System-paced secondary task under time pressure
Number of subjects: 39
Study 27082493 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation group (self-paced secondary task)
Number of subjects: 39
Study 27082493 — intervention group
Group type: COMPARATOR
Intervention: Baseline driving performance without distraction
Number of subjects: 39
Study 24625239 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (n=30)
Number of subjects: 93
Study 24625239 — intervention group
Group type: COMPARATOR
Intervention: Canola oil (n=33)
Number of subjects: 93
Study 24625239 — intervention group
Group type: COMPARATOR
Intervention: Control oil (n=30)
Number of subjects: 93
Study 23020132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg) plus trametinib (2 mg)
Number of subjects: 247
Study 23020132 — intervention group
Group type: COMPARATOR
Intervention: Dabrafenib monotherapy
Number of subjects: 247
Study 19996977 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day oral quadruple therapy regimen with omeprazole (20 mg, twice daily), tetracycline (750 mg, three times daily), metronidazole (500 mg, three times daily), and bismuth potassium citrate (300 mg, twice daily)
Number of subjects: 277
Study 19996977 — intervention group
Group type: COMPARATOR
Intervention: Placebo regimen
Number of subjects: 277
Study 18751503 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 75 mg capsule (test 1)
Number of subjects: 24
Study 15701488 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN) starting on postoperative day 3
Number of subjects: 42
Study 15701488 — intervention group
Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN) starting on postoperative day 3
Number of subjects: 42
Study 15701488 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 42
Study 15701488 — intervention group
Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 42
Study 12791430 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser-induced noxious stimuli (80% frequent) with rare stronger-intensity deviant stimuli (10% target, 10% distractor)
Number of subjects: 0
Study 12791430 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong stimuli delivered alone on one hand without instruction (100%, no-task stimuli)
Number of subjects: 0
Study 12791430 — intervention group
Group type: EXPERIMENTAL
Intervention: Distractor stimuli (10%)
Number of subjects: 0
Study 12791430 — intervention group
Group type: EXPERIMENTAL
Intervention: Target stimuli (10%)
Number of subjects: 0
Study 10619544 — intervention group
Group type: EXPERIMENTAL
Intervention: Focusing on electric shocks
Number of subjects: 60
Study 10619544 — intervention group
Group type: COMPARATOR
Intervention: Distraction from electric shocks
Number of subjects: 60
Study 10619544 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated administration of electric shocks
Number of subjects: 60
Study 7503006 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 46
Study 7503006 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 46
Study 1820293 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg captopril t.i.d.
Number of subjects: 90
Study 1820293 — intervention group
Group type: COMPARATOR
Intervention: 40 mg frusemide or placebo
Number of subjects: 90
Study 31755915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (up to 2 doses before surgery and every 3 weeks afterward until disease progression or unacceptable toxicities)
Number of subjects: 15
Study 31755915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 15
Study 31268624 — intervention group
Group type: COMPARATOR
Intervention: Certolizumab pegol
Number of subjects: 776
Study 31268624 — intervention group
Group type: COMPARATOR
Intervention: Abatacept
Number of subjects: 776
Study 31268624 — intervention group
Group type: COMPARATOR
Intervention: CT-P13 (biosimilar infliximab)
Number of subjects: 776
Study 28034710 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 7600
Study 28034710 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface ablation
Number of subjects: 7600
Study 28034710 — intervention group
Group type: EXPERIMENTAL
Intervention: ReLEx
Number of subjects: 7600
Study 28034710 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior chamber phakic IOL
Number of subjects: 7600
Study 28034710 — intervention group
Group type: EXPERIMENTAL
Intervention: Iris-supported phakic IOL
Number of subjects: 7600
Study 25788320 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-reducing salpingo-oophorectomy (RRSO)
Number of subjects: 934
Study 25618968 — intervention group
Group type: EXPERIMENTAL
Intervention: Anshendingzhi decoction (ASDZD)
Number of subjects: 78
Study 25618968 — intervention group
Group type: COMPARATOR
Intervention: Danzhixiaoyao pill (DZXYP)
Number of subjects: 78
Study 22738907 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Number of subjects: 0
Study 22738907 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control/delayed‐treatment condition
Number of subjects: 0
Study 18395716 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q(10), 200 mg/day
Number of subjects: 60
Study 18395716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17576043 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 5
Study 17576043 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 5
Study 15293818 — intervention group
Group type: EXPERIMENTAL
Intervention: TTO-gel (2.5 per cent)
Number of subjects: 49
Study 15293818 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) gel (0.2 per cent)
Number of subjects: 49
Study 15293818 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 49
Study 11165126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe extract treatment (ML-1 standardized mistletoe preparation)
Number of subjects: 477
Study 11165126 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mistletoe treatment)
Number of subjects: 477
Study 11165126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe extract treatment
Number of subjects: 477
Study 9710397 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol 25 microg/kg
Number of subjects: 60
Study 9710397 — intervention group
Group type: COMPARATOR
Intervention: Transnasal placebo
Number of subjects: 60
Study 7975966 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (3 mg vaginal tablet or 0.5 mg intracervical gel)
Number of subjects: 542
Study 2686737 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (twice or three times daily)
Number of subjects: 21
Study 2686737 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 21
Study 2686737 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 21
Study 782240 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium acid phosphate
Number of subjects: 71
Study 782240 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 71
Study 782240 — intervention group
Group type: COMPARATOR
Intervention: Low calcium diet only
Number of subjects: 71
Study 30576475 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation‐based balance training (PBT)
Number of subjects: 24
Study 30576475 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional intensive balance training (CIBT)
Number of subjects: 24
Study 30576475 — intervention group
Group type: COMPARATOR
Intervention: PBT and CIBT
Number of subjects: 24
Study 28753702 — intervention group
Group type: EXPERIMENTAL
Intervention: FICE-guided pCLE with targeted biopsies (group A)
Number of subjects: 238
Study 28753702 — intervention group
Group type: COMPARATOR
Intervention: FICE with standard biopsies (group B)
Number of subjects: 238
Study 28753702 — intervention group
Group type: EXPERIMENTAL
Intervention: FICE-guided pCLE with targeted biopsies
Number of subjects: 238
Study 28753702 — intervention group
Group type: EXPERIMENTAL
Intervention: pCLE-guided targeted biopsies
Number of subjects: 238
Study 25850528 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 15
Study 25850528 — intervention group
Group type: COMPARATOR
Intervention: Control Therapy (CT)
Number of subjects: 15
Study 23600363 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin in addition to αGI (Intake 1, 2, and 3 groups)
Number of subjects: 0
Study 23600363 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin in addition to αGI (Intake 3 group)
Number of subjects: 0
Study 23600363 — intervention group
Group type: COMPARATOR
Intervention: Alogliptin alone (Intake 0 group)
Number of subjects: 0
Study 21789887 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA Drink
Number of subjects: 14
Study 21789887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19404617 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg daily for 7 days)
Number of subjects: 0
Study 19404617 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg acute and 300 mg sub-acute)
Number of subjects: 0
Study 16940077 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin-tazobactam 12 g/1.5 g administered continuously over 24 h
Number of subjects: 262
Study 16940077 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of piperacillin-tazobactam 3 g/0.375 g administered over 30 min every 6 h for 4 to 14 days
Number of subjects: 262
Study 16940077 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin-tazobactam
Number of subjects: 262
Study 16940077 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of piperacillin-tazobactam
Number of subjects: 262
Study 16940077 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion and intermittent infusion
Number of subjects: 262
Study 14676594 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet with oral placebo for 5 months
Number of subjects: 28
Study 14676594 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet with oral vitamin E (400 mg/d x 2 months, 100 mg/d x 3 months)
Number of subjects: 28
Study 11196236 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with LCPUFA
Number of subjects: 0
Study 11196236 — intervention group
Group type: COMPARATOR
Intervention: Formula without LCPUFA
Number of subjects: 0
Study 11196236 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with LCPUFA (preterm infants)
Number of subjects: 0
Study 11196236 — intervention group
Group type: COMPARATOR
Intervention: Formula without LCPUFA (full-term infants)
Number of subjects: 0
Study 9310515 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Elevated Tilt Position (HETP)
Number of subjects: 12
Study 9310515 — intervention group
Group type: COMPARATOR
Intervention: Horizontal Position
Number of subjects: 12
Study 8379674 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM (5‐FU, ADM, MMC)
Number of subjects: 21
Study 8379674 — intervention group
Group type: COMPARATOR
Intervention: FEM (5‐FU, EPIR, MMC)
Number of subjects: 21
Study 3706498 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 73
Study 3706498 — intervention group
Group type: COMPARATOR
Intervention: Parent training
Number of subjects: 73
Study 31356703 — intervention group
Group type: EXPERIMENTAL
Intervention: massed PE (10 sessions delivered over 2 weeks)
Number of subjects: 331
Study 31356703 — intervention group
Group type: EXPERIMENTAL
Intervention: spaced PE (10 sessions delivered over 8 weeks)
Number of subjects: 331
Study 31356703 — intervention group
Group type: EXPERIMENTAL
Intervention: present‐centered therapy (PCT; 10 sessions delivered over 8 weeks)
Number of subjects: 331
Study 31356703 — intervention group
Group type: COMPARATOR
Intervention: minimal contact control (MCC; weekly therapist phone check‐in for 4 weeks)
Number of subjects: 331
Study 31356703 — intervention group
Group type: COMPARATOR
Intervention: spaced PE vs. PCT
Number of subjects: 331
Study 28567669 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 67
Study 28567669 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Continuous Training (MCT) group
Number of subjects: 67
Study 28567669 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) group
Number of subjects: 67
Study 28567669 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) group
Number of subjects: 67
Study 25633475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (12 or 24 weeks, once or twice per week)
Number of subjects: 216
Study 25633475 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (supervised, twice per week for 24 weeks)
Number of subjects: 216
Study 22647826 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy (amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg, lansoprazole 30 mg twice daily for 5 days)
Number of subjects: 270
Study 22647826 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (amoxicillin 1000 mg, clarithromycin 500 mg, lansoprazole 30 mg twice daily for 7 days)
Number of subjects: 270